Chiron Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Chiron Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$244K	Sell	1,542 -405	-21%	-$54.8K	0.22%	112
2026 Q1	$249K	Buy	+1,947	New	+$243K	0.25%	99
2025 Q3	$7.12M	Sell	71,084 -8,254	-10%	-$743K	6.1%	2
2025 Q2	$6.58M	Sell	79,338 -4,557	-5%	-$364K	5.72%	2
2025 Q1	$6.8M	Sell	83,895 -3,307	-4%	-$296K	6.18%	2
2024 Q4	$7.85M	Sell	87,202 -1,703	-2%	-$165K	7.41%	2
2024 Q3	$8.78M	Sell	88,905 -2,449	-3%	-$241K	7.77%	2
2024 Q2	$8.47M	Sell	91,354 -718	-0.8%	-$64.4K	8.09%	2
2024 Q1	$8.74M	Sell	92,072 -48,517	-35%	-$4.5M	7.94%	2
2023 Q4	$12.6M	Sell	140,589 -8,117	-5%	-$603K	10.92%	2
2023 Q3	$10.9M	Buy	148,706 +10,496	+8%	+$838K	9.34%	2
2023 Q2	$11.5M	Sell	138,210 -29,100	-17%	-$2.43M	9.11%	2
2023 Q1	$12.8M	Buy	167,310 +17,883	+12%	+$1.48M	8.86%	2
2022 Q4	$12.4M	Sell	149,427 -8,871	-6%	-$718K	8.63%	2
2022 Q3	$12.6M	Sell	158,298 -8,528	-5%	-$719K	8.44%	2
2022 Q2	$12.4M	Buy	166,826 +8,619	+5%	+$647K	7.82%	2
2022 Q1	$14.2M	Buy	158,207 +112,928	+249%	+$10.4M	8.96%	2
2021 Q4	$5.07M	Buy	45,279 +5,753	+15%	+$694K	3.66%	3
2021 Q3	$4.97M	Buy	39,526 +31,015	+364%	+$3.99M	3.62%	4
2021 Q2	$1.15M	Buy	8,511 +5,692	+202%	+$748K	0.96%	24
2021 Q1	$382K	Buy	2,819 +507	+22%	+$75.9K	0.32%	52
2020 Q4	$325K	Sell	2,312 -1,680	-42%	-$215K	0.27%	60
2020 Q3	$445K	Buy	+3,992	New	+$448K	0.36%	42

Other funds holding XBI

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

PSP Research Newtown Square, Pennsylvania $188M AUM

AAS

Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return

WAM

Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return

RFM

Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return

MFS

Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

SGH

Sivik Global Healthcare Greenwich, Connecticut $132M AUM 24.1% 1-Year Est. Return

EWM

Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return

LHWM

Lake Hills Wealth Management Austin, Texas $220M AUM 39.11% 1-Year Est. Return

MWA

MFA Wealth Advisors Pittsburgh, Pennsylvania $587M AUM 27.44% 1-Year Est. Return

Chiron Capital Management's XBI Position: Q2 2026 in Review

Chiron Capital Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 21% in Q2 2026, selling an estimated $54.8K and leaving 1,542 shares worth $244K. The position accounts for 0.22% of the portfolio, ranked #112.

Chiron Capital Management first reported a position in XBI in Q3 2020 and has held it in 23 quarters since. The position peaked at $14.2M in Q1 2022. 178 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Chiron Capital Management held 1,542 shares of State Street SPDR S&P Biotech ETF worth $244K as of Q2 2026.
Chiron Capital Management sold 405 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $54.8K.
State Street SPDR S&P Biotech ETF made up 0.22% of Chiron Capital Management's portfolio in Q2 2026, its #112 holding.
Chiron Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and has held it in 23 quarters since.
Chiron Capital Management's State Street SPDR S&P Biotech ETF position peaked at $14.2M in Q1 2022.
178 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Chiron Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.